Analystreport

VistaGen Therapeutics, Inc. (NASDAQ: VTGN) is now covered by analysts at Robert W. Baird. They set a "buy" rating and a $9.00 price target on the stock.

VistaGen Therapeutics, Inc.  (VTGN) 
Last vistagen therapeutics, inc. earnings: 2/13 04:30 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.vistagen.com